Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Peter Wirth Named Chairman of the FORMA Therapeutics Board of Directors



  Peter Wirth Named Chairman of the FORMA Therapeutics Board of Directors

Business Wire

WATERTOWN, Mass. -- November 13, 2012

FORMA Therapeutics today announced the appointment of Peter Wirth, former
Executive Vice President, Legal and Corporate Development, Chief Risk Officer
and Corporate Secretary of Genzyme, as Chairman of the Board of Directors. Mr.
Wirth will replace Alexis Borisy of Third Rock Ventures who is stepping down
from the Board.

“Peter’s experience building Genzyme into a leading global biotechnology firm
will be extremely valuable, as FORMA expands beyond the strength of its drug
discovery engine to develop transformational patient-tailored therapies,” said
Steven Tregay, Ph.D., Founder and CEO, FORMA Therapeutics. “His strategic,
financial and legal expertise will be a significant asset to the company and
our Board of Directors. We are very pleased to welcome him and extend our
gratitude to Alexis for his contributions and dedication to FORMA.”

“I am particularly excited to be joining Steve Tregay and the team at FORMA at
this exciting time in the company’s development,” said Peter Wirth. “Steve and
Ken Bair, FORMA’s Chief Scientific Officer, have built an innovative,
industrial-scale drug discovery platform, established important collaborations
with leaders in the pharmaceutical industry, and have added translational
science and clinical development capabilities through their strategic
relationship with Dr. Daniel Von Hoff and TGen Drug Development (TD2). I look
forward to contributing to this unique approach to building a sustainable
biotech company that can discover and develop transformative drugs to address
the needs of cancer patients.”

Peter Wirth is currently a 2012 Advanced Leadership Fellow at Harvard
University. Mr. Wirth served Genzyme Corporation as Secretary to the Board of
Directors and outside general counsel since 1982. From January 1996 through
May 2011, he was a senior executive at Genzyme, most recently serving as
Executive Vice President, Legal and Corporate Development, Chief Risk Officer
and Corporate Secretary. During this time, Mr. Wirth had senior management
responsibility for Genzyme’s legal function, its corporate development
function, its molecular oncology tracking stock division (Nasdaq: GZMO), its
non-absorbed polymer drug discovery and development division and its
enterprise risk management function. Mr. Wirth worked closely with Henri
Termeer, Genzyme’s CEO, to build the company from a small start-up to a
diversified enterprise with more than 12,000 employees in locations spanning
the globe and 2009 revenues of $4.5 billion. Genzyme was named a Fortune 500
company in 2010 and was acquired by Sanofi-Aventis in a transaction valued at
more than $20 billion in April 2011.

From 1975 through 1995, Mr. Wirth practiced law at Palmer & Dodge, a Boston
law firm, where he was head of the firm's biotechnology practice group. Mr.
Wirth acted as outside general counsel for a number of public and private
biotechnology companies, including companies working in the areas of
neuroscience, immunology, non-absorbable pharmaceuticals, gene therapy,
structure-based drug design, NMR imaging agents, and bioseparations. Mr. Wirth
also acted as special outside counsel to biotechnology and pharmaceutical
companies in the area of corporate collaborations and joint ventures. His
areas of legal expertise include venture capital financings, institutional
private placements, public offerings, off-balance sheet R&D financings such as
RDLPs and SWORDS, corporate collaborations, joint ventures and mergers and
acquisitions.

Mr. Wirth received his B.A. from the University of Wisconsin - Madison in 1972
and his J.D. from Harvard Law School in 1975. He currently serves as a
Director of Synageva BioPharma Corp. (Nasdaq: GEVA).

About FORMA Therapeutics

FORMA Therapeutics targets essential cancer pathways to create transformative
small molecule cancer therapies. FORMA’s novel approach to accessing high
value drug targets, many of which pose significant challenges to conventional
discovery approaches, leverages the integration of its innovative drug
discovery technologies and oncology expertise, enabling efficient screening,
discovery and rational development of small molecule drug candidates with
qualified cellular mechanisms of action. FORMA is leveraging translational and
clinical development capabilities through their strategic relationship with
Dr. Daniel Von Hoff and TGen Drug Development (TD2) to build a robust pipeline
of transformative cancer therapies in areas such as tumor metabolism,
epigenetics, protein homeostasis, and protein-protein interactions. FORMA is
headquartered in Watertown, MA. www.formatherapeutics.com

Contact:

MacDougall Biomedical Communications
Kari Watson or Charles Liles, 781-235-3060
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement